Mrs. Manjula Ramalingam, a 44-year-old widow, was diagnosed with B-cell Acute Lymphoblastic Leukemia in 2022. Despite undergoing intensive chemotherapy and immunotherapy, her disease has relapsed four times in three years and has now become resistant to conventional treatments. Classified as a high-risk patient, doctors have urgently recommended CAR T-cell therapy — a cutting-edge, personalized immunotherapy that reprograms the body’s immune cells to fight cancer.

Why CAR T-cell Therapy?
CAR T-cell therapy is the latest hope for patients like Manjula who do not respond to standard treatments. In India, this advanced therapy is available at leading hospitals with success rates over 70% in similar cases. However, the treatment cost is steep, estimated at around ₹70 lakhs (7 million INR), which includes hospital fees and specialized care.

About Manjula’s Situation
She lost her husband in 2018 and lives with her elderly parents and 12-year-old son. Having exhausted all her financial resources, she urgently needs our help to afford this life-saving treatment.

How You Can Help
Your generous contribution will directly fund her CAR T-cell therapy, hospital care, and related medical expenses. Every donation, big or small, brings her closer to a chance at remission and a healthier future.